Journal: EMBO Molecular Medicine
Article Title: A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities
doi: 10.1038/s44321-025-00237-z
Figure Lengend Snippet: ( A ) Quantification of fluorescence images after cilia inhibition. Both cell lines were either treated with DMSO alone, 50 nM and 250 nM of MBZ for 48 h before fixation. Each cilia was counted and the total number of cilia within each field normalized to the total number of nuclei within that field. Each captured field contained 25 tiles, and each tile was captured at a 63X magnification. n = 3 fields quantified per condition, data shown as mean ± SD. Unpaired t-test. GIC39R: * p = 0.0242 and ** p = 0.0057; GIC67R: * p = 0.0255 and ** p = 0.0039. ( B ) Left: surface plots of synergy scores obtained after combination treatment of MBZ and TMZ on recurrent GIC (top: Patient 39; bottom: Patient 67). n = 3 biologically independent experiments. Right: matrices reporting Loewe Synergy Scores obtained after combination treatment of MBZ and TMZ in GIC39R (top) or GIC67R (bottom). n = 3 independent biological experiments. ( C ) Venn diagram showing intersections of differentially expressed genes between XGIC and XGICR or IRGIC—samples processed for scRNAseq. Patient 39 on the left and patient 67 on the right. Both intersect presented a list of potential targets. Genes selected as potential recurrence patient-specific targets from the top 10 DE genes and the corresponding drugs which were selected are shown next to the relative Venn diagram. ( D ) Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Zonisamide (right, patient 67), Pyrimethamine (top left, patient 39) and TRAM34 (bottom left, Patient 39). Measurement of Area-under-Curve (AUC) and histograms representing mean AUC ± SD were used to compare the overall response to treatment. n = 4 independent biological experiments, unpaired t-test. * p = 0.037 (Zonisamide); ** p = 0.0028 (TRAM34); *** p = 0.0008 (Pyrimethamine).
Article Snippet: TRAM34 , Tocris , #2946.
Techniques: Fluorescence, Inhibition, Viability Assay, Derivative Assay
Alomone Labs is a verified supplier 
Alomone Labs manufactures this product 
